Unfortunately, war is the daily media lead. We get the numbers of dead and injured for each conflict. You might consider those just injured as ‘lucky’ if you’re like me. Au contraire. Familiar issues are traumatic brain and spine injuries. Alongside lost limbs and wounds caused by bomb debris and emotional symptoms such as PTSD and depression that may persist for years, sometimes a lifetime. (Xaigham.com)
For life-saving technologies, war has unfortunately become a growth sector. I take no pleasure in saying that.
A sudden, traumatic blow to the spine (tSCI) can fracture, dislocate, crush or compress one or more of the vertebrae. A gunshot or knife wound that penetrates and cuts the spinal cord also can cause a spinal cord injury. Additional damage usually occurs over days or weeks.
The global Spinal Cord Trauma Treatment market was valued at US$ 2458.9 million in 2022 and is projected to reach US$ 3009.4 million by 2029, at a CAGR of 2.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The current Middle East conflict was not included. Unfortunately, those projected growth numbers could rise significantly.
While I am using the wars and conflicts as examples of the growth of the traumatic injury market, it was already significant and this is just the US.
- A recent estimate of the annual incidence of traumatic spinal cord injury (CCI) is approximately 54 cases per one million people in the United States.
- The estimated number of people with tSCI living in the United States is approximately 302,000 persons, ranging from 255,000 to 383,000 persons.
- The average age at injury has increased from 29 during the 1970s to 43 since 2015.
- Traumatic brain injury (TBI) is defined as an alteration in brain function or other evidence of brain pathology caused by an external force. Examples of TBI include falls, assaults, motor vehicle accidents and sports injuries.
The question arises: how is this issue addressed? There are myriad companies, large and small, looking for answers.
TORONTO and HAIFA, Israel, Jan. 05, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries.
How does it work? Stay with me; it’s pretty straightforward.
Part One: Active Ingredients
Exosomes: Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Can be administered non-invasively, intranasally
Part Two: Delivery
ExoTherapy: Exosomes, loaded with therapeutic molecules, cross the blood-brain barrier and reach cells and tissues for regeneration, rewiring and recovery.
Part Three: Effect
SiRNA-PTEN: The suggested PTEN inhibition-based therapeutic targets are nerve growth and regeneration after injury or damage, treatment of cardiac ischemia/reperfusion and associated disease, wound repair, and infertility.
The goal is to reverse this traumatic brain trauma as well as develop other health issues such as depression—no small accomplishment. The US FDA has granted NRX Orphan Drug Status.
The Orphan Drug Designation program provides orphan status to drugs and biologics for rare diseases that meet specific criteria. Orphan drug designation provides incentives, including:
- Tax credits for qualified clinical trials
- Exemption from user fees
- Potential for seven years of market exclusivity after approval
“Orphan-drug designation is expected to streamline our go-to-market, shorten our regulatory process, save the Company millions of dollars, and provide valuable market exclusivity. We appreciate the formal recognition of the potential impact of our therapy on the lives of patients suffering from acute spinal cord injuries,” said Dr. Shaltiel, CEO of NurExone Biologic, Ltd.
The Company also holds an exclusive worldwide license from Technion and Tel Aviv University for developing and commercializing the technology.
This technology is not only promising but appears well destined for success. In their totality, the current NRX out-front therapies could bring much relief to those seriously ‘injured’ patients who live with chronic pain and myriad challenges daily.
NurExome is a cutting-edge medical technology company. While trading has been modest, it paints a positive investment picture for the previously reasons stated. Will it pop tomorrow? No. That I can guarantee.
A savvy plan would to be to approach as a dollar-cost average investment. The deeper you dig, the more potential will become apparent.
Note Hyperlinks below.
| Stock stats Jan 5 2024 | |
| 52 Week Range | 0.1000 0.4200 |
| Volume | 7,000 |
| Avg. Volume | 4,511 |
| Market Cap | 14.475M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1100 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.01 |
| In-depth Corporate Presentation Litchfield Research |
November 27, 2022
Marc CHALLANDE
Cannibble Foodtech (CSE: PLCN), an innovative Israeli food tech company that develops and manufactures food pix products with hemp, recently shared an update about the Eshbal Functional foods acquisition. This acquisition is an important milestone because Eshbal Functional foods will bring unique know-how and food technology. The accumulated experience of both managements will drive market success and rapid growth of the combined company in this high-growth sector of “better-for-you” food products.
About Cannibble Foodtech
Cannibble Foodtech (CSE: PLCN) develops and manufactures mixed products enhanced variously with hemp seeds and hemp protein, where legal to do so. The company has already produced more than 100 product SKUs, and 32 have been manufactured to date. The company’s products include a wide variety of many favors of premixed powder foods, beverages, nutritional supplements, spices & a unique line of products for athletes infused with Cannabinoids & Hemp protein.
Now, let’s focus on the Eshbal Functional foods acquisition. Eshbal develops and produces unique formulations: nutraceuticals, medicinal foods, sugar-free and gluten-free products, vegan products, syrups, and dry mixes, including sweeteners and a line of keto products. Eshbal focuses on developing unique formulations of functional food products that promote health beyond their nutritional values for retail brands, private labels, and B2B. The parties are in the final stage of negotiating the definitive agreement for the acquisition and expect to sign the definitive agreement to be signed in Q4 2022. Both companies have already started business cooperation even if the deal hasn’t been signed yet. Cannibble received two orders from a distributor in the United States that placed the two orders from Eshbal for one of Eshbal’s leading products. Cannibble is deeply convinced this acquisition will expand the company’s business in the United States in the gluten-free market.
About the acquisition terms, Eshbal will receive 51% of the issued and outstanding shares of Cannibble, and with Cannibble issuing up to another 20% (of the number of Cannibble Shares issued and outstanding at Closing) of Cannibble Shares to the Vendors subject to Eshbal achieving certain sales or profitability milestones within six years of Closing. Furthermore, Cannibble will complete a private placement with a minimum financing of $4.5M.
“We have approached a number of retail chain food buyers and distributors in the United States and we have received significant interest in Eshbal’s products portfolio. As part of our efforts, we have already received initial test orders from a food distributor in the United States. Once we complete the acquisition of Eshbal, we plan to increase the scope of Eshbal’s gluten free business in the US market.”
Yoav Bar-Joseph, CEO and director
About the hemp and cannabis market
The hemp market is set to have strong growth. Hemp and cannabis brands are reaching more consumers by investing in product innovation. The global industrial hemp market was valued at $4.9B in 2019 and is projected to reach $18.8B by 2027, registering a CAGR of 22.4% from 2021 to 2027. About the cannabis market, it was valued at $28.6B in 2020 and will witness stellar growth to top $197.74B by 2028, registering a CAGR of 32.04%. Cannabis has been used for thousands of years, and now, it is finally being recognized for its therapeutic and medicinal benefits. Medical hemp has gained a lot of worldwide attention in recent years, notably with the use and acceptance of medical C. Sativa, which continues to grow, as evidenced by an increasing number of countries and states permitting its use for specific medical indications. Countries such as Germany, Finland, Israel, and Canada have taken bold steps in allowing medical marijuana use owing to its therapeutic benefits. Additionally, more than 25 states in the US have changed their laws to legalize cannabis for medical use.
Another area CBD dives in is the wellness space. As consumers continue to spend on products they perceive to support their health and wellness goals, experts predict cannabis brands will have more opportunities than ever. Let’s focus on hemp seeds as an example. Hulled hemp seeds are rich in omega fatty acids, including omega-3 and omega-6. Omega fatty acids are essential for supporting your health and have been correlated with reduced chance of heart disease, reduced inflammation, and supported brain health. Also, hemp seeds are rich in minerals like phosphorus, sodium, zinc, magnesium, sulfur, calcium, and Vitamin E. Hemp seeds aren’t just superpowered with crucial vitamins and minerals. They’re also packed with 11 grams of protein per serving. One-quarter of the calories in hemp seeds come from their protein content, which is higher than other protein sources. Moreover, hemp seeds are a complete protein source, containing all the essential amino acids the body needs to function correctly.
Bottom line
Cannibble Foodtech (CSE: PLCN) is still in the early stage but is set to have tremendous growth. The acquisition of Eshbal Functional foods will allow Cannibble to expand its American opportunity, combined with Eshbal’s board experience. It will have better experience strategies to conquer more market share. The stock volume is currently low, but once the company declares more recurring sales, the stock volume and price should subsequently increase.
Marc has been involved in the Stock Market Media Industry for the last +4 years. After obtaining a college degree in engineering in France, he moved to Canada, where he created Money,eh?, a personal finance website. He then contributed to building Guerilla Capital, a Capital Markets company and FirstPhase Media where he is head of research. At10xAlerts, he writes articles and conducts interviews on many sectors, including technology, metals & mining markets.
-
Marc CHALLANDEhttps://10xalerts.com/author/marcchallande/
-
Marc CHALLANDEhttps://10xalerts.com/author/marcchallande/
-
Marc CHALLANDEhttps://10xalerts.com/author/marcchallande/
-
Marc CHALLANDEhttps://10xalerts.com/author/marcchallande/
All Articles
The latest
3 Small-cap Gold Juniors to Take Notice of $ELEM $GLDR $SOMA
Golden Rapture – The Most Undervalued Gold Exploration Company trading in the Junior Markets (CSE:GLDR)
INVESTMENT: THIS AI FIRM JUST RELEASED SOME GAME-CHANGING NEWS
Subscribe
©2024 10xAlerts